A conversation with Bob Eccles on ESG
Bob Eccles, Visiting Professor of Management Practice, Saïd Business School, University of Oxford; Founding Chairman of SASB Request link to Forum Presentation
A conversation with Bob Eccles on ESG Read More »
Bob Eccles, Visiting Professor of Management Practice, Saïd Business School, University of Oxford; Founding Chairman of SASB Request link to Forum Presentation
A conversation with Bob Eccles on ESG Read More »
Dennis Ostwald, CEO of the WifOR Institute, and Sonja Haut, Head Impact Valuation at Novartis, take us on a deep dive into health from the perspective of its economic impact, how Novartis is implementing impact valuation, and what this approach could mean for the Biopharma sector. Request link to Forum Presentation
Jens Reissmann, Project Lead for EU Taxonomy Reporting at Bayer, shared insights and practical learnings from Bayer’s work on fulfilling these critical new reporting requirements, and put it into the wider context of embedding Sustainability/ESG in management accounting, and preparing for ‘still to come’ external disclosure requirements.
BSRT Forum with Jens Reissmann Read More »
ESG Standards and Regulatory Progress with ECOFACT, an update on global policy developments around ESG that will affect biopharma directly or indirectly in the near-term. Fourth in an ongoing series tailored for BSRT participants. Request link to Forum Presentation
BSRT Forum with ECOFACT Read More »
Health Outcomes Observatory (H2O) with Meni Styliadou, H2O Founder and Co-Leader, Distinguished Fellow of the Data Sciences Institute and VP of Government Affairs, Public Policy, and Sustainable Healthcare at Takeda. In conversation with Francesco Patalano, H2O Working Group Leader and Head of Pediatric and Patient Reported Outcomes Centers of Excellence at Novartis, and Madeleine Brady, H2O Communications (Moderator). Request link to Forum Presentation
BSRT Forum with H2O Read More »
20+ Years of Sustainability Leadership – A conversation with Lars Rebien Sørensen
BSRT Forum – A conversation with Lars Rebien Sørensen Read More »
Continuing the dialog between biopharma leaders and capital markets representatives on how to structure effective, efficient, and decision-useful communications about ESG strategy and performance.
Biopharma Investor Workshop #4 Read More »
Towards a global perspective on Biopharma sustainability, hosted by the ESG Disclosure Study Group, Japan.
Biopharma Sustainability — A Global Perspective Read More »
Update on global hard and soft regulatory changes affecting biopharma.Focus on EU: Green Deal, Circular Economy, Sustainable Finance, Non-Financial Reporting Directive.Speaker: Olivier Jaeggi, Managing Director, ECO:FACT Request link to Forum Presentation
Regulatory and ESG Policy Outlook for Biopharma Read More »
Roundtable Forum with Lise Kingo.Biopharma sustainability oversight and governance priorities.Speaker: Lise Kingo, Independent Director, Sanofi; former Executive Director, UN Global Compact Request link to Forum Presentation
Business Leadership and Governance in Biopharma Read More »
Connecting Biopharma Sustainability and Long-Term Planning — A collaboration with CECP’s CEO Investor Forum. Initial release of our Executive Report and Practitioner’s Guide for integrating sustainability and long-term planning for biopharma companies. Watch Video
Is Biopharma Future-Proof? ESG and Long-Term Planning Read More »
A direct conversation between Biopharma sustainability leaders and sector investors about metrics for the sector’s highest-priority ESG topics.
Biopharma Investor Workshop #3 Read More »